Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention

Pietro Manuel Ferraro, Roberto Mangiacapra, Fabio Mangiacapra, Alessandro Sticchi, Edoardo Bressi, Michele Mattia Viscusi, Iginio Colaiori, Elisabetta Ricottini, Ilaria Cavallari, Silvia Spoto, Gian Paolo Ussia, Francesco Grigioni

Research output: Contribution to journalArticle

Abstract

We investigated the interaction between chronic kidney disease (CKD) and high platelet reactivity (HPR) in determining long-term clinical outcomes following elective PCI for stable coronary artery disease (CAD). A total of 500 patients treated with aspirin and clopidogrel were divided based on the presence of CKD (defined as glomerular filtration rate of < 60 ml/min/1.73 m2) and HPR (defined as a P2Y12 reaction unit value ≥ 240 at VerifyNow assay). Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5 years. Patients with both CKD and HPR showed the highest estimates of MACE (25.6%, p = 0.005), all-cause death (17.9%, p = 0.004), and cardiac death (7.7%, p = 0.004). The combination of CKD and HPR was an independent predictor of MACE (HR 3.12, 95% CI 1.46–6.68, p = 0.003). In conclusion, the combination of CKD and HPR identifies a cohort of patients with the highest risk of MACE at 5 years.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalJournal of Cardiovascular Translational Research
DOIs
Publication statusPublished - 2021

Keywords

  • Chronic kidney disease
  • Platelet reactivity
  • Percutaneous coronary intervention
  • Coronary artery disease

Fingerprint

Dive into the research topics of 'Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention'. Together they form a unique fingerprint.

Cite this